{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:20:08Z","timestamp":1790385608022,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2004,10,23]],"date-time":"2004-10-23T00:00:00Z","timestamp":1098489600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2004,11]]},"DOI":"10.1007\/s00228-004-0813-5","type":"journal-article","created":{"date-parts":[[2004,10,22]],"date-time":"2004-10-22T10:13:59Z","timestamp":1098440039000},"page":"673-677","source":"Crossref","is-referenced-by-count":35,"title":["Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): a case\/non-case study from the French Pharmacovigilance Database"],"prefix":"10.1007","volume":"60","author":[{"given":"S.","family":"Lugardon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lapeyre-Mestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. L.","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The French Network of Regional Pharmacovigilance Centres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2004,10,23]]},"reference":[{"key":"CR1","first-page":"119","volume":"12","author":"JL Montastruc","year":"2003","unstructured":"Montastruc JL (2003) Pharmacology: selective for whom? Marketing ploy. Prescrire Int 12:119","journal-title":"Prescrire Int"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","volume":"343","author":"C Bombardier","year":"2000","unstructured":"Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ, VIGOR Study group (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343:1520?1528","journal-title":"N Engl J Med"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","volume":"284","author":"FE Silverstein","year":"2000","unstructured":"Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284:1247?1255","journal-title":"JAMA"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1046\/j.1365-2125.2003.01763.x","volume":"55","author":"D Layton","year":"2003","unstructured":"Layton D, Riley J, Wilton LV, Shakir SA (2003) Safety profile of rofecoxib as used in general practice in England: results of a prescription-event monitoring study. Br J Clin Pharmacol 55:166?174","journal-title":"Br J Clin Pharmacol"},{"key":"CR5","first-page":"93","volume":"14","author":"WHO","year":"2000","unstructured":"WHO (2000) Celecoxib: adverse reaction reports. WHO Drug Inf 14:93?94","journal-title":"WHO Drug Inf"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1046\/j.1365-2125.1997.00652.x","volume":"44","author":"AC Egberts","year":"1997","unstructured":"Egberts AC, Meyboom RH, De Koning FH, Bakker A, Leufkens HG (1997) Non-puerperal lactation associated with antidepressant drug use. Br J Clin Pharmacol 44:277?281","journal-title":"Br J Clin Pharmacol"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1046\/j.1365-2125.1997.00615.x","volume":"44","author":"N Moore","year":"1998","unstructured":"Moore N, Kreft-Jais C, Haramburu F, Noblet C, Andrejak M, Ollagnier M, Begaud B (1998) Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case\/non-case study in the French pharmacovigilance system database. Br J Clin Pharmacol 44:513?518","journal-title":"Br J Clin Pharmacol"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00002018-200225060-00010","volume":"25","author":"AC Egberts","year":"2002","unstructured":"Egberts AC, Meyboom RH, van Puijenbroek EP (2002) Use of measures of disproportionality in pharmacovigilance: three Dutch examples. Drug Saf 25:453?458","journal-title":"Drug Saf"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/0895-4356(92)90158-J","volume":"45","author":"BH Stricker","year":"1992","unstructured":"Stricker BH, Tijssen JG (1992) Serum sickness-like reactions to cefaclor. J Clin Epidemiol 45:1177?1184","journal-title":"J Clin Epidemiol"},{"key":"CR10","first-page":"557","volume":"50","author":"N Moore","year":"1995","unstructured":"Moore N, Noblet C, Kreft-Jais C, Lagier G, Ollagnier M, Imbs JL (1995) French pharmacovigilance database system: examples of utilisation. Therapie 50:557?562","journal-title":"Therapie"},{"key":"CR11","first-page":"adverse","volume":"drugs","author":"WHO","year":"1992","unstructured":"WHO (1992) International monitoring of adverse reactions to drugs: adverse reaction terminology. WHO collaborating Centre for International Drug Monitoring, Uppsala","journal-title":"International monitoring of adverse reactions to"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","volume":"356","author":"IR Edwards","year":"2000","unstructured":"Edwards IR, Aronson JK (2000) Adverse drug reactions: definitions, diagnosis, and management. Lancet 356:1255?1259","journal-title":"Lancet"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1001\/jama.282.20.1929","volume":"282","author":"MJ Langman","year":"1999","unstructured":"Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ (1999) Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 282:1929?1933","journal-title":"JAMA"},{"key":"CR14","first-page":"111","volume":"40","author":"B Begaud","year":"1985","unstructured":"Begaud B, Evreux JC, Jouglard J, Lagier G (1985) Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie 40:111?118","journal-title":"Therapie"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1136\/gut.52.9.1265","volume":"52","author":"TM MacDonald","year":"2003","unstructured":"MacDonald TM, Morant SV, Goldstein JL, Burke TA, Pettitt D (2003) Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs. Gut 52:1265?1270","journal-title":"Gut"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1002\/sim.1157","volume":"21","author":"PG Heijden Van der","year":"2002","unstructured":"Van der Heijden PG, van Puijenbroek EP, van Buuren S, van der Hofstede JW (2002) On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of under-reporting on odds ratios. Stat Med 21:2027?2044","journal-title":"Stat Med"},{"key":"CR17","first-page":"87","volume":"46","author":"K Desboeuf","year":"1998","unstructured":"Desboeuf K, Lapeyre-Mestre M, Montastruc JL (1998) Risk of gastrointestinal haemorrhage with calcium antagonists. Br J Clin Pharmacol 46:87?89","journal-title":"Br J Clin Pharmacol"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1046\/j.1365-2125.2003.01968.x","volume":"57","author":"AM Wilson","year":"2004","unstructured":"Wilson AM, Thabane L, Holbrook A (2004) Application of data mining data in pharmacovigilance. Br J Clin Pharmacol 57:127?134","journal-title":"Br J Clin Pharmacol"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/0016-5085(93)90952-9","volume":"105","author":"D Henry","year":"1993","unstructured":"Henry D, Dobson A, Turner C (1993) Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology 105:1078?1088","journal-title":"Gastroenterology"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/00001648-200109000-00018","volume":"12","author":"L Garcia-Rodriguez","year":"2001","unstructured":"Garcia-Rodriguez L, Hernandez-Diaz S (2001) Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 12:570?576","journal-title":"Epidemiology"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1136\/bmj.325.7365.624","volume":"325","author":"M Mamdani","year":"2002","unstructured":"Mamdani M, Rochon PA, Juurlink DN, Kopp A, Anderson GM, Naglie G, Austin J, Laupacis A (2002) Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 325:624","journal-title":"BMJ"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2165\/00002018-200427060-00005","volume":"27","author":"JR Laporte","year":"2004","unstructured":"Laporte JR, Ibanez L, Vidal X, Vendrell L, Leone R (2004) Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf 27:411?420","journal-title":"Drug Saf"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1136\/bmj.38068.716262.F7","volume":"328","author":"M Mamdani","year":"2004","unstructured":"Mamdani M, Juurlink DN, Kopp A, Naglie G, Austin PC, Laupacis A (2004) Gastrointestinal bleeding after the introduction of COX 2 inhibitors: ecological study. BMJ 328:1415?1416","journal-title":"BMJ"},{"key":"CR24","first-page":"551","volume":"290","author":"CC Chan","year":"1999","unstructured":"Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, Gordon R, Gresser M, Guay J, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini J, O? Neill GP, Ouellet M, Patrick D, Percival MD, Perrier H, Prasit P, Rodger I et al (1999) Rofecoxib [Vioxx, MK-0966; 4-(4?-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 290:551?560","journal-title":"J Pharmacol Exp Ther"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0140-6736(91)90744-A","volume":"337","author":"JR Laporte","year":"1991","unstructured":"Laporte JR, Carne X, Vidal X, Moreno V, Juan J (1991) Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Catalan Countries Study on Upper Gastrointestinal Bleeding. Lancet 337:85?89","journal-title":"Lancet"},{"key":"CR26","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(94)91843-0","volume":"343","author":"LA Garcia Rodriguez","year":"1994","unstructured":"Garcia Rodriguez LA, Jick H (1994) Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 343:769?772","journal-title":"Lancet"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-004-0813-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-004-0813-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-004-0813-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T08:41:34Z","timestamp":1558687294000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-004-0813-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10,23]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2004,11]]}},"alternative-id":["813"],"URL":"https:\/\/doi.org\/10.1007\/s00228-004-0813-5","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,10,23]]}}}